Clinical Trials Logo

Respiratory Syncytial Viruses clinical trials

View clinical trials related to Respiratory Syncytial Viruses.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06077968 Recruiting - Clinical trials for Respiratory Syncytial Viruses

A Study to Learn About ABRYSVO Vaccine in Older Adults to Prevent Severe Respiratory Syncytial Virus (RSV) Infection.

Start date: November 1, 2023
Phase:
Study type: Observational

The main purpose of this study is to learn about the effectiveness of Pfizer's ABRYSVO vaccine. This vaccine helps to prevent infections caused by Respiratory Syncytial Virus (RSV). RSV is a virus that can cause infections in the airways. These symptoms can be cold-like symptoms, but in some cases can lead to severe symptoms or hospitalization. This study uses only healthcare data that are already collected from routine visits to healthcare providers. This means that participants will not be actively enrolled in the study and there are no study treatments. The study will look at data for about two years. This study will look at patient information from: - Adults ages 60 years and older - Are eligible to receive the ABRYSVO vaccination